BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy

Keyphrases

Publications

volume 38, number 4, 2024

Laura Bender Somme, Christos Chouaid, Fabien Moinard-Butot, Jean-Baptiste Barbe-Richaud, Laurent Greillier, Roland Schott
Antibody-Drug Conjugates as Novel Therapeutic Agents for Non-Small Cell Lung Carcinoma with or without Alterations in Oncogenic Drivers. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 38 (4) (2024)
Marcin Stajszczyk, Krzysztof Batko, Zbigniew Michał Żuber, Brygida Kwiatkowska, Magdalena Krajewska-Włodarczyk, Bogdan Batko
Charting the Etanercept Journey: Tracing Cost Dynamics in Poland's Off-Patent Market from Reference Drug Rivalry to Biosimilar Monopoly. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 38 (4) (2024)
Yujie Liu, Jianhua Xie, Zhuxiang Li, Xiong Mei, Di Cao, Shengfeng Li, Linda Engle, Suli Liu, Hans C Ebbers, Cuihua Liu
Demonstration of Physicochemical and Functional Similarity of the Biosimilar BAT1806/BIIB800 to Reference Tocilizumab. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 38 (4) (2024)
Laura Bender Somme, Christos Chouaid, Fabien Moinard-Butot, Jean-Baptiste Barbe-Richaud, Laurent Greillier, Roland Schott
Antibody-Drug Conjugates as Novel Therapeutic Agents for Non-Small Cell Lung Carcinoma with or without Alterations in Oncogenic Drivers. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 38 (4) (2024)
Chad Rieger, Judith A Dean, Lisa Hall, Paola Vasquez, Gregory Merlo
Barriers and Enablers Affecting the Uptake of Biosimilar Medicines Viewed Through the Lens of Actor Network Theory: A Systematic Review. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 38 (4) (2024)
Marcin Stajszczyk, Krzysztof Batko, Zbigniew Michał Żuber, Brygida Kwiatkowska, Magdalena Krajewska-Włodarczyk, Bogdan Batko
Charting the Etanercept Journey: Tracing Cost Dynamics in Poland's Off-Patent Market from Reference Drug Rivalry to Biosimilar Monopoly. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 38 (4) (2024)
Amy L Lightner, Peter M Irving, Graham M Lord, Aline Betancourt
Stem Cells and Stem Cell-Derived Factors for the Treatment of Inflammatory Bowel Disease with a Particular Focus on Perianal Fistulizing Disease: A Minireview on Future Perspectives. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 38 (4) (2024)
Helen W Wong, Vivian H Nguyen, Timothy Y Mok, Fang Niu, Merta Cushing, Michael Lam, Stephanie L Ho, Lisa Y Law, Ashraf R Aziz, Rita L Hui
Outcomes of Rituximab-abbs versus Rituximab in Patients with Diffuse Large B-Cell Lymphoma in a Noninferiority Study. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 38 (4) (2024)
Yujie Liu, Jianhua Xie, Zhuxiang Li, Xiong Mei, Di Cao, Shengfeng Li, Linda Engle, Suli Liu, Hans C Ebbers, Cuihua Liu
Demonstration of Physicochemical and Functional Similarity of the Biosimilar BAT1806/BIIB800 to Reference Tocilizumab. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 38 (4) (2024)
Amy L Lightner, Peter M Irving, Graham M Lord, Aline Betancourt
Stem Cells and Stem Cell-Derived Factors for the Treatment of Inflammatory Bowel Disease with a Particular Focus on Perianal Fistulizing Disease: A Minireview on Future Perspectives. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 38 (4) (2024)
Chad Rieger, Judith A Dean, Lisa Hall, Paola Vasquez, Gregory Merlo
Barriers and Enablers Affecting the Uptake of Biosimilar Medicines Viewed Through the Lens of Actor Network Theory: A Systematic Review. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 38 (4) (2024)
Marcin Stajszczyk, Krzysztof Batko, Zbigniew Michał Żuber, Brygida Kwiatkowska, Magdalena Krajewska-Włodarczyk, Bogdan Batko
Charting the Etanercept Journey: Tracing Cost Dynamics in Poland's Off-Patent Market from Reference Drug Rivalry to Biosimilar Monopoly. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 38 (4) (2024)
John S Schardt, Neelan S Sivaneri, Peter M Tessier
Monoclonal Antibody Generation Using Single B Cell Screening for Treating Infectious Diseases. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 38 (4) (2024)
Yujie Liu, Jianhua Xie, Zhuxiang Li, Xiong Mei, Di Cao, Shengfeng Li, Linda Engle, Suli Liu, Hans C Ebbers, Cuihua Liu
Demonstration of Physicochemical and Functional Similarity of the Biosimilar BAT1806/BIIB800 to Reference Tocilizumab. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 38 (4) (2024)
Richard H Woods
Postmarketing Reports of Incomplete Dosing-Related Complications with Self-Injected PCSK9 Inhibitors: A Descriptive Study and Disproportionality Analysis. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 38 (4) (2024)
Jennifer D Wu
Emerging Innate Immune Cells in Cancer Immunotherapy: Promises and Challenges. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 38 (4) (2024)
Angela Sang, Selena Zhuo, Adara Bochanis, José E Manautou, Raman Bahal, Xiao-Bo Zhong, Theodore P Rasmussen
Mechanisms of Action of the US Food and Drug Administration-Approved Antisense Oligonucleotide Drugs. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 38 (4) (2024)
Helen W Wong, Vivian H Nguyen, Timothy Y Mok, Fang Niu, Merta Cushing, Michael Lam, Stephanie L Ho, Lisa Y Law, Ashraf R Aziz, Rita L Hui
Outcomes of Rituximab-abbs versus Rituximab in Patients with Diffuse Large B-Cell Lymphoma in a Noninferiority Study. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 38 (4) (2024)
Amy L Lightner, Peter M Irving, Graham M Lord, Aline Betancourt
Stem Cells and Stem Cell-Derived Factors for the Treatment of Inflammatory Bowel Disease with a Particular Focus on Perianal Fistulizing Disease: A Minireview on Future Perspectives. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 38 (4) (2024)
Chad Rieger, Judith A Dean, Lisa Hall, Paola Vasquez, Gregory Merlo
Barriers and Enablers Affecting the Uptake of Biosimilar Medicines Viewed Through the Lens of Actor Network Theory: A Systematic Review. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 38 (4) (2024)
Laura Bender Somme, Christos Chouaid, Fabien Moinard-Butot, Jean-Baptiste Barbe-Richaud, Laurent Greillier, Roland Schott
Antibody-Drug Conjugates as Novel Therapeutic Agents for Non-Small Cell Lung Carcinoma with or without Alterations in Oncogenic Drivers. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 38 (4) (2024)
Yujie Liu, Jianhua Xie, Zhuxiang Li, Xiong Mei, Di Cao, Shengfeng Li, Linda Engle, Suli Liu, Hans C Ebbers, Cuihua Liu
Demonstration of Physicochemical and Functional Similarity of the Biosimilar BAT1806/BIIB800 to Reference Tocilizumab. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 38 (4) (2024)
Angela Sang, Selena Zhuo, Adara Bochanis, José E Manautou, Raman Bahal, Xiao-Bo Zhong, Theodore P Rasmussen
Mechanisms of Action of the US Food and Drug Administration-Approved Antisense Oligonucleotide Drugs. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 38 (4) (2024)
Chad Rieger, Judith A Dean, Lisa Hall, Paola Vasquez, Gregory Merlo
Barriers and Enablers Affecting the Uptake of Biosimilar Medicines Viewed Through the Lens of Actor Network Theory: A Systematic Review. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 38 (4) (2024)
John S Schardt, Neelan S Sivaneri, Peter M Tessier
Monoclonal Antibody Generation Using Single B Cell Screening for Treating Infectious Diseases. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 38 (4) (2024)
Yujie Liu, Jianhua Xie, Zhuxiang Li, Xiong Mei, Di Cao, Shengfeng Li, Linda Engle, Suli Liu, Hans C Ebbers, Cuihua Liu
Demonstration of Physicochemical and Functional Similarity of the Biosimilar BAT1806/BIIB800 to Reference Tocilizumab. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 38 (4) (2024)
Laura Bender Somme, Christos Chouaid, Fabien Moinard-Butot, Jean-Baptiste Barbe-Richaud, Laurent Greillier, Roland Schott
Antibody-Drug Conjugates as Novel Therapeutic Agents for Non-Small Cell Lung Carcinoma with or without Alterations in Oncogenic Drivers. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 38 (4) (2024)
Marcin Stajszczyk, Krzysztof Batko, Zbigniew Michał Żuber, Brygida Kwiatkowska, Magdalena Krajewska-Włodarczyk, Bogdan Batko
Charting the Etanercept Journey: Tracing Cost Dynamics in Poland's Off-Patent Market from Reference Drug Rivalry to Biosimilar Monopoly. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 38 (4) (2024)
Jennifer D Wu
Emerging Innate Immune Cells in Cancer Immunotherapy: Promises and Challenges. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 38 (4) (2024)
Amy L Lightner, Peter M Irving, Graham M Lord, Aline Betancourt
Stem Cells and Stem Cell-Derived Factors for the Treatment of Inflammatory Bowel Disease with a Particular Focus on Perianal Fistulizing Disease: A Minireview on Future Perspectives. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 38 (4) (2024)
Richard H Woods
Postmarketing Reports of Incomplete Dosing-Related Complications with Self-Injected PCSK9 Inhibitors: A Descriptive Study and Disproportionality Analysis. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 38 (4) (2024)
Richard H Woods
Postmarketing Reports of Incomplete Dosing-Related Complications with Self-Injected PCSK9 Inhibitors: A Descriptive Study and Disproportionality Analysis. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 38 (4) (2024)

volume 38, number 5, 2024

Ashish Srinivasan, Daniel van Langenberg, Peter De Cruz, Jonathan Segal, Abhinav Vasudevan, Richard N Upton
Treatment Targets Should Influence Choice of Infliximab Dose Intensification Strategy in Inflammatory Bowel Disease: A Pharmacokinetic Simulation Study. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 38 (5) (2024)
Ashish Srinivasan, Daniel van Langenberg, Peter De Cruz, Jonathan Segal, Abhinav Vasudevan, Richard N Upton
Treatment Targets Should Influence Choice of Infliximab Dose Intensification Strategy in Inflammatory Bowel Disease: A Pharmacokinetic Simulation Study. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 38 (5) (2024)
Yan Zhao, Jing-Yi Li, Bin Yang, Yang-Feng Ding, Li-Ming Wu, Li-Tao Zhang, Jin-Yan Wang, Qian-Jin Lu, Chun-Lei Zhang, Fu-Ren Zhang, Xiao-Hong Zhu, Yu-Mei Li, Xiao-Hua Tao, Qing-Chun Diao, Lin-Feng Li, Jian-Yun Lu, Xiao-Yong Man, Fu-Qiu Li, Xiu-Juan Xia, Jiao-Ran Song, Ying-Min Jia, Li-Bo Zhang, Bo Chen, Jian-Zhong Zhang
Long-Term Efficacy and Safety of Stapokibart in Adults with Moderate-to-Severe Atopic Dermatitis: An Open-Label Extension, Nonrandomized Clinical Trial. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 38 (5) (2024)
Anne Holtermann, Mila Gislon, Martin Angele, Marion Subklewe, Michael von Bergwelt-Baildon, Kirsten Lauber, Sebastian Kobold
Prospects of Synergy: Local Interventions and CAR T Cell Therapy in Solid Tumors. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 38 (5) (2024)
Anne Holtermann, Mila Gislon, Martin Angele, Marion Subklewe, Michael von Bergwelt-Baildon, Kirsten Lauber, Sebastian Kobold
Prospects of Synergy: Local Interventions and CAR T Cell Therapy in Solid Tumors. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 38 (5) (2024)
Marina Beraza-Millor, Julen Rodríguez-Castejón, Ana Del Pozo-Rodríguez, Alicia Rodríguez-Gascón, María Angeles Solinís Aspiazu
Systematic Review of Genetic Substrate Reduction Therapy in Lysosomal Storage Diseases: Opportunities, Challenges and Delivery Systems. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 38 (5) (2024)
Ashish Srinivasan, Daniel van Langenberg, Peter De Cruz, Jonathan Segal, Abhinav Vasudevan, Richard N Upton
Treatment Targets Should Influence Choice of Infliximab Dose Intensification Strategy in Inflammatory Bowel Disease: A Pharmacokinetic Simulation Study. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 38 (5) (2024)
Anne Holtermann, Mila Gislon, Martin Angele, Marion Subklewe, Michael von Bergwelt-Baildon, Kirsten Lauber, Sebastian Kobold
Prospects of Synergy: Local Interventions and CAR T Cell Therapy in Solid Tumors. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 38 (5) (2024)
Hannah A Blair
Insulin Icodec: First Approval. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 38 (5) (2024)
Alessandra Zanetti, Rosella Tomanin
Targeting Neurological Aspects of Mucopolysaccharidosis Type II: Enzyme Replacement Therapy and Beyond. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 38 (5) (2024)
Alessandra Zanetti, Rosella Tomanin
Targeting Neurological Aspects of Mucopolysaccharidosis Type II: Enzyme Replacement Therapy and Beyond. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 38 (5) (2024)
Marina Beraza-Millor, Julen Rodríguez-Castejón, Ana Del Pozo-Rodríguez, Alicia Rodríguez-Gascón, María Angeles Solinís Aspiazu
Systematic Review of Genetic Substrate Reduction Therapy in Lysosomal Storage Diseases: Opportunities, Challenges and Delivery Systems. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 38 (5) (2024)
Hannah A Blair
Insulin Icodec: First Approval. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 38 (5) (2024)
Marina Beraza-Millor, Julen Rodríguez-Castejón, Ana Del Pozo-Rodríguez, Alicia Rodríguez-Gascón, María Angeles Solinís Aspiazu
Systematic Review of Genetic Substrate Reduction Therapy in Lysosomal Storage Diseases: Opportunities, Challenges and Delivery Systems. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 38 (5) (2024)
Capucine Arrivé, Caroline Bazzoli, Thomas Jouve, Johan Noble, Lionel Rostaing, Françoise Stanke-Labesque, Zoubir Djerada
A Population Pharmacokinetic Model of Tocilizumab in Kidney Transplant Patients Treated for Chronic Active Antibody-Mediated Rejection: Comparison of Plasma Exposure Between Intravenous and Subcutaneous Administration Schemes. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 38 (5) (2024)
Capucine Arrivé, Caroline Bazzoli, Thomas Jouve, Johan Noble, Lionel Rostaing, Françoise Stanke-Labesque, Zoubir Djerada
A Population Pharmacokinetic Model of Tocilizumab in Kidney Transplant Patients Treated for Chronic Active Antibody-Mediated Rejection: Comparison of Plasma Exposure Between Intravenous and Subcutaneous Administration Schemes. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 38 (5) (2024)
Alessandra Zanetti, Rosella Tomanin
Targeting Neurological Aspects of Mucopolysaccharidosis Type II: Enzyme Replacement Therapy and Beyond. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 38 (5) (2024)
Yan Zhao, Jing-Yi Li, Bin Yang, Yang-Feng Ding, Li-Ming Wu, Li-Tao Zhang, Jin-Yan Wang, Qian-Jin Lu, Chun-Lei Zhang, Fu-Ren Zhang, Xiao-Hong Zhu, Yu-Mei Li, Xiao-Hua Tao, Qing-Chun Diao, Lin-Feng Li, Jian-Yun Lu, Xiao-Yong Man, Fu-Qiu Li, Xiu-Juan Xia, Jiao-Ran Song, Ying-Min Jia, Li-Bo Zhang, Bo Chen, Jian-Zhong Zhang
Long-Term Efficacy and Safety of Stapokibart in Adults with Moderate-to-Severe Atopic Dermatitis: An Open-Label Extension, Nonrandomized Clinical Trial. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 38 (5) (2024)